Role of platelet-activating factor and prostanoids in hemodynamic changes in rat experimental endotoxic shock

被引:5
|
作者
Ebara, T
Miura, K
Matsuura, T
Imanishi, M
Yamano, Y
Kim, S
Iwao, H
机构
[1] OSAKA CITY UNIV,SCH MED,DEPT PHARMACOL,OSAKA 545,JAPAN
[2] OSAKA CITY UNIV,SCH MED,DEPT ORTHOPAED SURG,OSAKA 545,JAPAN
[3] OSAKA CITY GEN HOSP,OSAKA 534,JAPAN
来源
JAPANESE JOURNAL OF PHARMACOLOGY | 1996年 / 71卷 / 03期
关键词
endotoxin; platelet-activating factor; cyclooxygenase; hemodynamics;
D O I
10.1254/jjp.71.247
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The present experiments were conducted to elucidate the role of platelet-activating factor (PAF) and cyclooxygenase products in the cardiovascular responses to endotoxin in anesthetized rats. Endotoxin (10 mg/kg, i.v.) induced hypotension that was accompanied by a decrease in cardiac output and an increase in calculated total peripheral resistance, suggesting that this hypotension mainly resulted from the reduced cardiac output. The endotoxin-induced decrease in cardiac output and hemoconcentration was significantly attenuated by TCV-309 (a PAF receptor antagonist), ibuprofen (a cyclooxygenase inhibitor) or S-1452 (a thromboxane A(2)/prostaglandin H-2-receptor antagonist). During the 3-hr observation period following endotoxin administration, ibuprofen and S-1452 showed only early protection and TCV-309 showed late attenuation of the endotoxin-induced hypotension. Tachycardiac responses to endotoxin were only blocked by ibuprofen but not by TCV-309 or S-1452. These results suggest that both PAF and cyclooxygenase product(s), including thromboxane A(2), mediate the decrease in cardiac output and hypotension in rat experimental endotoxic shock. Cyclooxygenase product(s) other than thromboxane A(2) or prostaglandin endoperoxide may be involved in the endotoxin-induced increase in heart rate.
引用
收藏
页码:247 / 253
页数:7
相关论文
共 50 条
  • [41] PLATELET-ACTIVATING FACTOR
    WYKLE, RL
    OFLAHERTY, JT
    THOMAS, MJ
    METHODS IN ENZYMOLOGY, 1988, 163 : 44 - 54
  • [42] PLATELET-ACTIVATING FACTOR
    MARTIN, J
    LANCET, 1988, 2 (8626-7): : 1486 - 1486
  • [43] PLATELET-ACTIVATING FACTOR
    CUSACK, NJ
    NATURE, 1980, 285 (5762) : 193 - 193
  • [44] Platelet-activating factor
    Owen, John S.
    Thomas, Michael J.
    Wykle, Robert L.
    LIPIDOMICS AND BIOACTIVE LIPIDS: LIPIDS AND CELL SIGNALING, 2007, 434 : 105 - 116
  • [45] PLATELET-ACTIVATING FACTOR
    PINCKARD, RN
    HOSPITAL PRACTICE, 1983, 18 (11): : 67 - 76
  • [46] PLATELET-ACTIVATING FACTOR
    VALONE, FH
    WESTERN JOURNAL OF MEDICINE, 1989, 150 (03): : 334 - 334
  • [47] EVIDENCE AGAINST A ROLE FOR PLATELET-ACTIVATING FACTOR IN HYPOXIC PULMONARY VASOCONSTRICTION IN THE RAT
    MCCORMACK, DG
    BARNES, PJ
    EVANS, TW
    CLINICAL SCIENCE, 1989, 77 (04) : 439 - 443
  • [48] EVIDENCE FOR THE ROLE OF PLATELET-ACTIVATING FACTOR IN IMMUNE-COMPLEX VASCULITIS IN THE RAT
    WARREN, JS
    MANDEL, DM
    JOHNSON, KJ
    WARD, PA
    JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (02): : 669 - 678
  • [49] Platelet-activating factor plays a pivotal role in the induction of experimental lung injury
    Miotla, JM
    Jeffery, PK
    Hellewell, PG
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1998, 18 (02) : 197 - 204
  • [50] GLOMERULAR RESPONSES TO PLATELET-ACTIVATING FACTOR IN THE RAT - ROLE OF THROMBOXANE-A2
    BADR, KF
    DEBOER, DK
    TAKAHASHI, K
    HARRIS, RC
    FOGO, A
    JACOBSON, HR
    AMERICAN JOURNAL OF PHYSIOLOGY, 1989, 256 (01): : F35 - F43